arrow
M

Michel Tchan

University College London Hospitals NHS Foundation Trust
H指数:31
被引数:3,121

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5 Years of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results

成人鞘磷脂酶缺乏症患者经Olipudase Alfa酶替代疗法治疗5年后临床结局持续改善:ASCEND试验最终结果

2026-04-280
OAAI
2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C

2025年尼曼-皮克病C型的共识临床管理指南

2026-04-260
OAAI
Targeted Long-Read Sequencing as a Single Assay Improves the Diagnosis of Spastic-Ataxia Disorders
2025-02-251
OA
The Frequencies of Different Inborn Errors of Metabolism in Adult Metabolic Centres: 10 Years Later, Another Report From the SSIEM Adult Metabolic Physicians Group

不同遗传代谢病在成人代谢中心的频率:10年后,SSIEM成人代谢医师组的另一份报告

2025-02-060
PRE
Final results of the ASCEND trial: Continued or sustained improvements in hepatosplenomegaly, respiratory outcomes, and lipid profile after 4 years of olipudase alfa enzyme replacement therapy in adults with acid sphingomyelinase deficiency
2025-02-010
PRE
Shaping the future of kidney genetics in Australia: proceedings from the KidGen policy implementation workshop 2023
2024-08-172
OAAI
Implementation and Evaluation of a National Multidisciplinary Kidney Genetics Clinic Network Over 10 Years
2024-08-016
OAAI
Genome sequencing reanalysis increases the diagnostic yield in dystonia
2024-07-010
OAAI
Genomic Testing in Patients with Kidney Failure of an Unknown Cause A National Australian Study
2024-05-032
OAAI
Preliminary results from the ongoing aphenity extension study: Sepiapterin reduces blood PHE with improved dietary PHE tolerance in participants with phenylketonuria
2024-04-010
PRE
Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial
2023-12-028
OAAI
Treatment of HMG-CoA Lyase Deficiency-Longitudinal Data on Clinical and Nutritional Management of 10 Australian Cases

Hmg-coa裂解酶缺乏症的治疗-10例澳大利亚病例的临床和营养管理的纵向数据

2023-01-192
OAAI
Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire

依格列净治疗Ib型糖原贮积病的疗效和安全性: 来自国际问卷的数据

2022-08-0140
OA
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results
2022-07-0139
OA